Lupin has launched Topiramate Extended-Release capsules, in different strengths, in the United States. Bioequivalent to Supernus Pharmaceuticals’ Trokendi XR capsules and indicated for the treatment of certain types of seizures, the product launch follows U.S. FDA approval for Lupin’s abbreviated new drug application. Topiramate ER capsules had an estimated annual sale of $164 million in the U.S., the company said, citing IQVIA MAT Dec 2025 numbers. Lupin shares closed 1.04% higher at ₹2,217.40 each on the BSE on Thursday. Published – February 05, 2026 11:04 pm IST Share this: Click to share on WhatsApp (Opens in new window) WhatsApp Click to share on Facebook (Opens in new window) Facebook Click to share on Threads (Opens in new window) Threads Click to share on X (Opens in new window) X Click to share on Telegram (Opens in new window) Telegram Click to share on LinkedIn (Opens in new window) LinkedIn Click to share on Pinterest (Opens in new window) Pinterest Click to email a link to a friend (Opens in new window) Email More Click to print (Opens in new window) Print Click to share on Reddit (Opens in new window) Reddit Click to share on Tumblr (Opens in new window) Tumblr Click to share on Pocket (Opens in new window) Pocket Click to share on Mastodon (Opens in new window) Mastodon Click to share on Nextdoor (Opens in new window) Nextdoor Click to share on Bluesky (Opens in new window) Bluesky Like this:Like Loading... Post navigation Webinar on biotechnology education to be held on February 8 UPSC expands conditions for attempting CSEs after being allotted for IPS, Group A Services